NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an Outperform rating and a $6.00 price target. The report reviews the company's lead programs, including its broad-spectrum antiviral candidate NV-387, along with longer-term development initiatives. NanoViricides noted that while it provided publicly available information and answered technical questions, the analyst independently developed all estimates, financial models and projections.
Separately, the company announced that President and Executive Chairman Anil R. Diwan participated in a Fireside Chat published by StockInvestor Daily's IPO-Edge program, where he discussed NanoViricides' antiviral technology platform, the potential of NV-387 against multiple viral diseases and variants, the company's regulatory progress, including FDA Orphan Drug Designation and its Rare Pediatric Disease Designation filing for measles, as well as the resurgence of infectious diseases such as measles, mpox and Ebola. To view the full press release, visit https://ibn.fm/7XBbY.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug planned for treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials. Another advanced drug candidate is NV-HHV-1 for the treatment of Shingles.
The company's platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of human viral diseases including HIV/AIDS, Hepatitis B, Hepatitis C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Asian Bird Flu, Dengue, Japanese Encephalitis, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if initial research is successful.
The initiation of coverage by Noble Capital Markets provides independent validation of NanoViricides' technology and pipeline, potentially increasing investor visibility and confidence. The $6 price target suggests significant upside from current trading levels, indicating the analyst's optimism about the company's prospects.
